​

Iovance Biotherapeutics Ownership | Who Owns Iovance Biotherapeutics?


OverviewForecastRevenueFinancialsChartTranscripts

Iovance Biotherapeutics Ownership Summary


Iovance Biotherapeutics is owned by 60.88% institutional investors, 0.35% insiders, and 38.77% retail investors. Blackrock funding, inc. /de is the largest institutional shareholder, holding 8.42% of IOVA shares. Vanguard Morn Total Stk Mkt Idx Investor is the top mutual fund, with 3.02% of its assets in Iovance Biotherapeutics shares.

IOVA Ownership Benchmark


TypeName% Inst% Insiders% Retail
StockIovance Biotherapeutics60.88%0.35%38.77%
SectorHealthcare Stocks 129.28%12.06%-41.34%
IndustryBiotech Stocks 181.42%11.67%-93.09%

Institutional Shareholders


Top Institutional Shareholders by Total Shares

HolderShares% HoldingValue
Blackrock funding, inc. /de37.90M8.42%$561.74M
Mhr fund management28.97M8.11%$101.67M
Blackrock21.23M7.97%$170.23M
Vanguard group27.21M7.47%$74.28M
State street21.70M4.82%$321.52M
Vanguard capital management18.40M4.09%$272.64M
Two sigma investments, lp13.69M3.83%$48.04M
Vanguard portfolio management12.28M2.73%$181.99M
Millennium management9.41M2.63%$33.04M
Goldman sachs group8.76M2.45%$30.75M

Top Institutional Shareholders by % of Total Assets

HolderShares% AssetsValue
Knott david m jr1.17M9.44%$17.27M
Orion investment2.08M8.19%$30.88M
Mhr fund management28.97M7.43%$101.67M
Rhenman & partners asset management ab2.50M4.11%$37.09M
B group1.50M3.90%$5.26M
Palo alto investors lp6.35M3.41%$22.29M
Xcelsior advisor partners1.84M1.83%$27.29M
Kennondale capital management188.24K1.81%$2.79M
Invenomic capital management lp8.50M1.37%$29.82M
Virtus investment advisers413.11K1.35%$6.12M

Top Buyers

HolderShares% AssetsChange
Two sigma investments, lp13.69M0.04%9.29M
D. e. shaw8.02M0.02%4.19M
Vanguard group27.21M0.00%3.15M
Millennium management9.41M0.01%2.83M
Price t rowe associates inc /md/3.17M0.00%1.98M

Top Sellers

HolderShares% AssetsChange
Hood river capital management---9.22M
Long focus capital management2.10M0.19%-6.50M
Macquarie group---4.79M
Artisan partners limited partnership---4.41M
Avoro capital advisors---3.50M

New Positions

HolderShares% AssetsChangeValue
Arrowstreet capital, limited partnership1.12M0.01%1.12M$16.56M
Voloridge investment management1.02M0.01%1.02M$3.59M
Artal group1.01M0.21%1.01M$8.11M
First trust advisors lp649.13K0.01%649.13K$9.62M
Norges bank416.24K0.00%416.24K$3.08M

Sold Out

HolderChange
Nbc securities-4.00
Global financial private client-4.00
Smallwood wealth investment management-9.00
Pier 88 investment partners-10.00
Capital performance advisors llp-11.00

Institutional Ownership Trends


DateHoldingsChange %SharesChange %OwnershipChange %Increased PositionChange %Decreased PositionChange %
Sep 30, 20263194.59%274,052,979-5.43%601.47%1802.86%8427.27%
Jun 30, 20263040.66%291,042,3558.15%641.56%179-4.79%626.90%
Mar 31, 2026150-45.05%64,023,711-75.53%170.35%88-41.72%29-54.69%
Dec 31, 2025168-35.63%143,064,086-32.81%390.97%89-29.37%43-41.89%
Sep 30, 20252470.82%212,726,6064.22%631.71%118-4.07%69-1.43%

Top Mutual Funds Shareholders


HolderShares% HoldingChange
Vanguard Morn Total Stk Mkt Idx Investor13.49M3.02%1.01M
Vanguard Total Stock Mkt Idx Inv13.49M3.02%1.01M
Vanguard MStar Total Stk Mkt Idx Invest13.55M2.99%38.52K
Vanguard US Total Market Shares ETF8.71M2.66%762.45K
State Street® SPDR® S&P® Biotech ETF12.07M2.61%314.70K
iShares Russell 2000 ETF10.08M2.18%-
Hood River Small-Cap Growth Instl5.10M1.53%-
Macquarie Small Cap Core I4.08M1.22%56.67K
Vanguard Small Cap Index4.85M1.07%-32.16K
SPDR® S&P Biotech ETF3.56M0.98%7.96K

Recent Insider Transactions


DateNameRoleActivityValue
Jun 05, 2025Kirby Daniel Gordon Chief Commercial OfficerBuy$55.20K
May 23, 2025Puri Raj K. Chief Regulatory OfficerBuy$9.74K
May 14, 2025Vogt Frederick G Interim CEO & General CounselBuy$42.25K
Nov 12, 2024Maynard Ryan D-Sell$503.00K
Feb 20, 2024MCPEAK MERRILL A-Buy$2.29M

Insider Transactions Trends


DateBuySell
2026 Q4--
2026 Q3--
2026 Q2--
2026 Q1--
2025 Q4--

IOVA Ownership FAQ


Who Owns Iovance Biotherapeutics?

Iovance Biotherapeutics shareholders are primarily institutional investors at 60.88%, followed by 0.35% insiders and 38.77% retail investors. The average institutional ownership in Iovance Biotherapeutics's industry, Biotech Stocks , is 181.42%, which Iovance Biotherapeutics falls below.

Who owns the most shares of Iovance Biotherapeutics?

Iovance Biotherapeutics’s largest shareholders are Blackrock funding, inc. /de (37.9M shares, 8.42%), Mhr fund management (28.97M shares, 8.11%), and Blackrock (21.23M shares, 7.97%). Together, they hold 24.50% of Iovance Biotherapeutics’s total shares outstanding.

Does Blackrock own Iovance Biotherapeutics?

Yes, BlackRock owns 7.97% of Iovance Biotherapeutics, totaling 21.23M shares as of Jun 2024. This represents 0.00% of BlackRock's total assets, with a market value of 170.23M$. In the last quarter, BlackRock increased its holdings by 1.3M shares, a 6.50% change.

Who is Iovance Biotherapeutics’s biggest shareholder by percentage of total assets invested?

Knott david m jr is Iovance Biotherapeutics’s biggest shareholder by percentage of total assets invested, with 9.44% of its assets in 1.16M Iovance Biotherapeutics shares, valued at 17.27M$.

Who is the top mutual fund holder of Iovance Biotherapeutics shares?

Vanguard Morn Total Stk Mkt Idx Investor is the top mutual fund holder of Iovance Biotherapeutics shares, with 3.02% of its total shares outstanding invested in 13.49M Iovance Biotherapeutics shares.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

  • Customize your own personal stocks lists, views and charts

  • Choose from hundreds of fields, up to 15 years of history

  • Conduct deep comparison analysis

  • Discover trending investment themes

  • Find your next best investment

  • Research stocks using tools